Company Performance - Teladoc reported a quarterly loss of $0.19 per share, better than the Zacks Consensus Estimate of a loss of $0.27, and an improvement from a loss of $0.28 per share a year ago, representing an earnings surprise of +29.63% [1] - The company posted revenues of $631.9 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.77%, although this is a decrease from year-ago revenues of $642.44 million [2] - Over the last four quarters, Teladoc has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - Teladoc shares have underperformed the market, losing about 9.8% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.21 on revenues of $627.2 million, and for the current fiscal year, it is -$1.21 on revenues of $2.51 billion [7] Industry Context - The Medical Services industry, to which Teladoc belongs, is currently in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% of industries [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry outlook can materially impact stock performance [5][8]

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Visa (V) came out with quarterly earnings of $2.98 per share, beating the Zacks Consensus Estimate of $2.86 per share. This compares to earnings of $2.42 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +4.20%. A quarter ago, it wa ...

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Tango Therapeutics, Inc. due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Tango Therapeutics is expected to report a quarterly loss of $0.35 per share, reflecting a year-over-year change of -45.8% [3]. - Revenues are projected to be $6.19 million, down 68.9% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.62% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Tango Therapeutics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.57% [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Tango Therapeutics currently holds a Zacks Rank of 2, suggesting a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Tango Therapeutics was expected to post a loss of $0.34 per share but actually reported a loss of -$0.36, resulting in a surprise of -5.88% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Context - Krystal Biotech, another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $1.08 for the same quarter, indicating a year-over-year change of +25.6% [18]. - Revenues for Krystal Biotech are expected to be $90.5 million, up 28.8% from the previous year [18].

Company Performance - Bandwidth (BAND) reported quarterly earnings of $0.38 per share, exceeding the Zacks Consensus Estimate of $0.32 per share, and up from $0.29 per share a year ago, representing an earnings surprise of +18.75% [1] - The company posted revenues of $180.01 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.75% and increasing from $173.6 million year-over-year [2] - Over the last four quarters, Bandwidth has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.38 on revenues of $190.5 million, and for the current fiscal year, it is $1.53 on revenues of $750.4 million [7] - The company's earnings outlook and management's commentary on the earnings call will be crucial for assessing the sustainability of the stock's price movement [3][4] Industry Context - Bandwidth operates within the Zacks Communication - Infrastructure industry, which is currently ranked in the top 21% of over 250 Zacks industries, indicating a favorable industry outlook [8] - The performance of Bandwidth's stock may be influenced by the overall industry trends, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]

JetBlue Airways (JBLU) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of +48.39%. A quarter ago, it was expected that this airline would post a loss of $0.61 per share when it actually produced a loss of $0.59, delivering a surprise of +3.28%. Over the last four quarters, the company has ...

Group 1 - The report indicates that the trading logic is driven by improved profit expectations rather than reality, with average weekly trading volume in the stock market rising from approximately 1.5 trillion to over 1.8 trillion since the end of June, although a marginal weakening was observed last week [1][12] - The "anti-involution" and "Yajiang" phenomena have boosted trading sentiment, enhancing risk appetite from both supply and demand sides, with the market preemptively trading on future profit improvements [1][12] - Economic pressures are expected to increase in the second half of the year, with the A-share market potentially exhibiting a seesaw effect in August and September, making monetary policy a key timing consideration for the third quarter [1][12] Group 2 - The first phase of "anti-involution" is ongoing, with a return to the essence of distribution and demand expected after the initial heat subsides. The first phase focuses on cyclical trading, influenced by supply-side reforms since 2016, which have altered market perceptions of excessive competition in related industries [2][13] - The essence of "anti-involution" is to break the vicious cycle of "low price → reduced quality → internal competition" based on improved production efficiency from supply-side reforms, aiming for sustainable development through fair distribution [2][13] - Industry allocation is categorized over time, starting with cyclical expansion (currently favoring specialized chemicals), followed by emerging industries (solar energy, automotive, lithium batteries), then social welfare (education, healthcare, childbirth), and finally consumption [2][13] Group 3 - The report highlights ongoing challenges such as deflation, weak profits, and poor demand, with the timing of monetary policy easing being crucial for sustaining the stock market in the second half of the year [3][14] - The GDP deflator index has been in negative territory for nine consecutive quarters, indicating deflationary pressure, although the second quarter GDP growth exceeded 5% due to a low base [3][14] - The overall pre-announcement rate for A-share companies is only 44%, with net profit growth declining compared to Q1, reflecting that the profit side is still stabilizing at a low point [3][14] Group 4 - Key upcoming dates include August 12 for tariffs, August 22 for the last special treasury bond issuance of the year, and the political bureau meeting in September or October, which will influence policy timing based on economic data strength [4][20] - The report suggests that after taking profits in the steel sector, attention should shift to the first phase of "anti-involution" expansion, particularly in specialized chemicals [4][20] - The anticipated resolution of trade negotiations in the third quarter is expected to gradually materialize, with tariffs having a moderate impact on inflation, and profit expectations and risk appetite likely to continue driving risk assets upward [4][22] Group 5 - The report emphasizes that the resolution of trade negotiations will temporarily boost market risk appetite, but this focus will gradually fade in future trading [6][23] - The impact of tariffs on inflation at the consumer level is expected to be relatively limited, as businesses may absorb most of the tariff costs, with wholesale and retail profit margins declining [7][29] - Despite a significant nominal retail sales increase in June, actual retail sales growth remains weak, indicating that rising prices are suppressing consumption volume growth [7][30] Group 6 - The strategy recommends continuing to go long on US stocks and maintaining a strategic bullish outlook on the US dollar, while holding a bearish steep view on US bonds [8][36] - The report suggests that the Federal Reserve is not in a hurry to act, as inflation and employment data do not present immediate risks, allowing for a wait-and-see approach [8][36] - The anticipated limited impact of tariffs on inflation and the significant political pressure on the Federal Reserve suggest that there may only be one rate cut throughout the year [8][36]

Market Performance - Developed markets outperformed last week, with MSCI global index up by 1.3%, MSCI developed markets up by 1.4%, and MSCI emerging markets up by 0.7% [3] - Among developed markets, Nikkei 225 had the strongest performance (+4.1%), while S&P/ASX 200 was the weakest (-1.0%) [3] - In emerging markets, ChiNext Index was the best performer (+2.8%), while India’s Sensex 30 was the worst (-0.4%) [3] Trading Sentiment - Trading volume increased in Hong Kong and European markets, while it decreased in the US market [10][11] - Hong Kong's Hang Seng Index saw a trading volume of 186 billion shares and a turnover of 705.5 billion USD, reflecting a week-on-week increase [11] - The short-selling ratio in Hong Kong decreased to 11.5%, indicating high investor sentiment [11] Valuation - Developed markets' overall valuation improved, with the latest PE and PB ratios at 23.8x and 3.8x, respectively, placing them in the 93% and 100% percentile levels since 2010 [13] - Nasdaq and Dow Jones Industrial Average had the highest PE ratios at 43.1x and 32.0x, respectively [13] - Emerging markets also saw a valuation increase, with PE and PB ratios at 16.5x and 2.0x, respectively, in the 86% and 92% percentile levels since 2010 [14] Fund Flows - Global macro liquidity expectations tightened, with significant capital inflows into France, Germany, and India, while outflows were noted from the US [19][21] - In Hong Kong, a total of 21.3 billion HKD flowed into the market, with stable foreign capital inflows of 13.4 billion HKD [21] Earnings Expectations - Hong Kong's consumer sector saw an upward revision in earnings expectations, with the Hang Seng Index's 2025 EPS forecast adjusted from 2215 to 2210 [22] - The US S&P 500's earnings expectations remained stable at 265, while the Eurozone's STOXX50 index saw a slight downward adjustment from 338 to 337 [22][23]

Core Viewpoint - Tilray Brands, Inc. reported quarterly earnings of $0.02 per share, surpassing the Zacks Consensus Estimate of a loss of $0.03 per share, marking an earnings surprise of +166.67% [1] - The company posted revenues of $224.54 million for the quarter ended May 2025, which was 6.46% below the Zacks Consensus Estimate and a decrease from $229.88 million year-over-year [2] Financial Performance - The earnings report indicates a significant improvement from a loss of $0.04 per share a year ago [1] - Over the last four quarters, Tilray Brands has exceeded consensus EPS estimates twice, but has not beaten revenue estimates during the same period [2] Stock Performance - Tilray Brands shares have declined approximately 48.2% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for Tilray Brands is 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $209.71 million, and for the current fiscal year, it is -$0.17 on revenues of $885.29 million [7] - The outlook for the Medical - Products industry, to which Tilray Brands belongs, is currently in the bottom 30% of Zacks industries, which may negatively impact stock performance [8]

Core Insights - GeneDx Holdings Corp. has consistently surpassed earnings estimates, averaging a 202.27% beat over the last two quarters [1][2] - The company reported earnings of $0.28 per share against a consensus estimate of $0.11, resulting in a surprise of 154.55% for the last quarter [2] - For the previous quarter, earnings were $0.7 per share compared to an expected $0.2, delivering a surprise of 250.00% [2] Earnings Estimates and Predictions - Estimates for GeneDx Holdings have been trending higher due to its history of earnings surprises [5] - The stock has a positive Zacks Earnings ESP of +5.26%, indicating bullish sentiment among analysts regarding future earnings [8] - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) suggests a strong likelihood of another earnings beat in the upcoming report [8] Earnings ESP and Market Behavior - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [7] - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [9]

Core Viewpoint - Illinois Tool Works Inc. (ITW) is expected to report second-quarter 2025 results on July 30, with earnings estimates showing a positive trend and a history of surpassing consensus estimates [1][14]. Revenue and Earnings Estimates - The consensus estimate for revenues is $4.01 billion, reflecting a 0.4% decrease from the previous year [2]. - Adjusted earnings are estimated at $2.56 per share, indicating a 0.8% increase year over year [2]. Segment Performance Expectations - The Food Equipment segment is anticipated to see a revenue increase of 0.3% year over year to $668.8 million, driven by growth in institutional markets and strong demand in Europe [3]. - The Welding segment's revenues are expected to decline by 0.1% to $465.3 million, impacted by softness in industrial markets despite recovery in Asia Pacific and the Middle East [4]. - The Specialty Products segment is projected to decrease by 0.2% to $448.2 million, affected by weakness in the filter medical business [6]. - The Polymers & Fluids segment is expected to decline by 1.7% to $446.3 million, influenced by softness in body and tire repair businesses [6]. - The Automotive OEM segment is forecasted to decrease by 2.3% to $795.8 million due to a lower North American auto build rate [7]. - The Test & Measurement and Electronics segment is expected to see a revenue drop of 1.1% to $670.4 million, impacted by declining demand in the semiconductor market [8]. - The Construction Products segment is projected to decrease by 0.3% to $502.4 million, affected by lower demand in commercial and residential markets [10]. Margin and Cost Management - ITW's gross margin is expected to increase by 70 basis points to 44.5% due to effective cost management and enterprise initiatives [7][9]. Earnings Prediction - ITW has an Earnings ESP of +1.19%, suggesting a potential earnings beat, with the most accurate estimate at $2.59 per share [12].